{"filing":{"accession_number":"0001493152-26-029779","cik":"0002025774","ticker":"ALPWF","company_name":"Alps Group Inc","form":"6-K","filing_date":"2026-06-23","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2025774/000149315226029779/form6-k.htm"},"events":[{"id":13144,"run_id":11665,"accession_number":"0001493152-26-029779","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Alps Group Inc announced a Research and Collaboration Agreement with Dr. Kong Wai Mun to launch a patient-derived organoid (PDO) program for personalized cancer care in Southeast Asia. This represents a material expansion into precision oncology testing and a new business line, with the company targeting Malaysia's first clinically validated PDO platform. The announcement describes a strategic operational initiative involving new clinical partnerships (six major oncology centers identified), regulatory pathways (MREC ethics approval and MDA registration), and a national PDO biobank, which would affect a reasonable investor's assessment of the company's growth strategy and market positioning.","company_name":"Alps Group Inc","ticker":"ALPWF","filing_date":"2026-06-23","form":"6-K","submitted_at":null,"items":[{"id":10209,"accession_number":"0001493152-26-029779","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Alps Group Inc announced a Research and Collaboration Agreement with Dr. Kong Wai Mun to launch a patient-derived organoid (PDO) program for personalized cancer care in Southeast Asia. This represents a material expansion into precision oncology testing and a new business line, with the company targeting Malaysia's first clinically validated PDO platform. The announcement describes a strategic operational initiative involving new clinical partnerships (six major oncology centers identified), regulatory pathways (MREC ethics approval and MDA registration), and a national PDO biobank, which would affect a reasonable investor's assessment of the company's growth strategy and market positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:07:07.029950+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10209,"accession_number":"0001493152-26-029779","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Alps Group Inc announced a Research and Collaboration Agreement with Dr. Kong Wai Mun to launch a patient-derived organoid (PDO) program for personalized cancer care in Southeast Asia. This represents a material expansion into precision oncology testing and a new business line, with the company targeting Malaysia's first clinically validated PDO platform. The announcement describes a strategic operational initiative involving new clinical partnerships (six major oncology centers identified), regulatory pathways (MREC ethics approval and MDA registration), and a national PDO biobank, which would affect a reasonable investor's assessment of the company's growth strategy and market positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:07:07.029950+00:00","company_name":"Alps Group Inc","ticker":"ALPWF","filing_date":"2026-06-23"}]}